Listen "Meet the Reluctant Founder who is waging war on Antibiotic Resistant Infections!"
Episode Synopsis
Our guest today is another Atlanta luminary, Dr. Marvin
Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections.
It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.
How can this trend be stopped?
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim
Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections.
It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.
How can this trend be stopped?
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim
Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.
More episodes of the podcast Life Science and Biotech CEO stories
Success Lessons from a Serial Entrepreneur
14/05/2025
Patient Advocacy is NOT optional!
19/03/2025
What Pharma really thinks about Startups
14/08/2024
How this founder raised $230MM in capital
12/06/2024
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.